UBS raised the firm’s price target on Veracyte (VCYT) to $46 from $43 and keeps a Buy rating on the shares post the earnings report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT: